Key Drivers
- High liquidity
- Deep losses
- Negative FCF
AIAI Summary
CRSP has shifted from a speculative R&D story to a capital‑market‑funded hybrid commercial/development company where valuation now pivots on Casgevy's near‑term commercial ramp and the dilution/convertible‑overhang from recent financings. Monitor monthly Casgevy revenue versus analyst 2026 ramps, payer coverage/physician uptake, and convertible note conversion timelines—failure to materially accelerate sales would likely force dilutive financing and >30% downside risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High liquidity
- •Deep losses
- •Negative FCF
CRSP has a strong liquidity and low-leverage balance sheet (~$1.98B cash/investments, current ratio 13.3) but is suffering severe operating losses, negative FCF and negligible revenue, creating a high near-term burn risk.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •Rising volatility
- •Lower highs/lows
CRSP slid into a clear short-term downtrend over the last month—closing at $46.24 well below the ~$51.40 SMA with high volatility (peak $61.74 to low $46.24, ~25% drop), signaling bearish momentum unless buyers push price back above the SMA.
Rapid ~25% collapse from $61.74 on 2026-02-26 to $46.24 on 2026-03-20
Sentiment & News
Key News Insights:
- •Strategic pivot
- •Convertible raise
- •Share volatility
CRISPR is raising sizable convertible debt while pivoting beyond Casgevy into cardiovascular and autoimmune franchises amid mixed analyst views and near-term share weakness.
The financing supports longer-term franchise expansion but increases dilution and execution risk, likely keeping pressure on the stock in the near term
Similar Companies in Healthcare
Other companies in the same sector with AI ratings